In this article, we will discuss the 10 Best Future Stocks to Buy for the Next 5 Years.
On March 25, Scott Chronert of Citi joined ‘Closing Bell’ on CNBC to discuss whether it is time to enter the market and if recent presidential actions have changed the market dynamic. In the short term, Chronert noted that market positioning had been skewed negatively over the past three weeks as the conflict in Iran unfolded.
He suggested that any perceived alleviation of risk regarding the duration of that conflict would lead to a more positive tape, which accounts for the market’s behavior over the last day or two. On the flip side, Chronert explained that the intermediate-term outlook remains different and more complex. He emphasized the need to monitor specific inputs, including how oil prices trade over the intermediate term and the resulting implications for interest rates and currency. Furthermore, he pointed to the importance of upcoming corporate fundamentals as the market enters the Q1 reporting period.
While he acknowledged that the short-term outlook appears positive, he cautioned that there is still wood to chop for the intermediate term. Furthermore, Chronert explained that the earlier thesis for the year, which involved a broadening of the market into small-cap, mid-cap, and other non-tech sectors, was predicated on Goldilocks economics, a soft landing, and an easier Federal Reserve. However, as oil prices remain longer and higher, those economic assumptions become more problematic for the market’s broader sectors.
Our Methodology
We sifted through financial media reports to find stocks with multi-year growth opportunities. We then used screeners to identify stocks that are expected to grow their earnings by at least 25% over the next 5 years, and limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Note: All data was sourced on April 3.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
10 Best Future Stocks to Buy for the Next 5 Years
10. STMicroelectronics (NYSE:STM)
STMicroelectronics (NYSE:STM) is one of the best future stocks to buy for the next 5 years. On March 17, STMicroelectronics announced the expansion of its 800 VDC power conversion portfolio through the introduction of new 12V and 6V architectures developed in collaboration with Nvidia. These solutions complement the company’s existing 800 VDC to 50V stage and are designed to support the 800 VDC reference design.
This expansion aims to provide a complete portfolio for power distribution within gigawatt-scale AI datacenter infrastructure, using STMicroelectronics’ (NYSE:STM) power, analog, and mixed-signal technologies with custom chip and package-level designs. The new architectures address the industry’s shift toward diverse server configurations and power delivery topologies required for high-density AI infrastructures.
While the 12V converter enables high-efficiency distribution from rack-level power shelves to advanced AI accelerators, the 6V path allows OEMs to move the bus closer to the GPU. These developments help reduce copper usage, minimize resistive losses, and improve transient performance. The 50V, 12V, and 6V intermediate DC buses are expected to coexist depending on specific rack density, GPU configuration, and cooling strategies. Technically, the direct 800 VDC to 12V conversion eliminates traditional intermediate stages to reduce system-level losses and simplify integration for future GPU generations.
STMicroelectronics (NYSE:STM) is a technology company that specializes in semiconductor products and operates through four segments: AM&S (Analog products, MEMS & Sensors Group), P&D (Power and Discrete products), EMP (Embedded Processing), and D&RF (RF Products).
9. Bloom Energy Corporation (NYSE:BE)
Bloom Energy Corporation (NYSE:BE) is one of the best future stocks to buy for the next 5 years. On March 26, Bloom Energy announced the appointment of Simon Edwards as Chief Financial Officer, effective April 13. Edwards brings ~20 years of experience in scaling technology companies, with a background that combines operational rigor and expertise in digital infrastructure.
This hire aligns with the company’s focus on addressing power availability constraints currently impacting the growth of the AI industry. Edwards joins Bloom Energy from Groq, where he served as CEO and CFO, overseeing global financial operations and infrastructure expansion during a period of rapid growth. His career includes CFO roles at SaaS leaders Conga and ServiceMax, as well as senior leadership positions at GE, including CFO of GE Digital.
His professional history provides a foundation in manufacturing, digital transformation, and data-driven operational excellence across various tech sectors. According to Founder and CEO KR Sridhar, Edwards’ engineering background and experience with AI infrastructure will strengthen the management team as Bloom Energy Corporation (NYSE:BE) builds power platforms for the digital economy.
Bloom Energy Corporation (NYSE:BE) is an electrical equipment & parts company that specializes in solid oxide fuel cell systems for on-site power generation. The company also provides the Bloom Energy Server to convert fuel into electricity.
8. TKO Group Holdings Inc. (NYSE:TKO)
TKO Group Holdings Inc. (NYSE:TKO) is one of the best future stocks to buy for the next 5 years. On March 10, TKO Group announced a $1 billion share repurchase initiative, consisting of an $800 million accelerated share repurchase/ASR agreement and a 10b5-1 trading plan for up to $200 million. These actions are part of the company’s previously established $2 billion share repurchase authorization.
Under the terms of the ASR Agreement, TKO Group was to pay $800 million to Morgan Stanley & Co. LLC on March 11. The company expects an initial delivery of 3,136,179 shares of Class A common stock, with the final number of shares determined by the volume-weighted average price during the agreement’s term. These transactions are scheduled to conclude in June this year, nearly exhausting the total $2 billion authorization.
The secondary component of the announcement involves a 10b5-1 trading plan, which is set to commence once the ASR Agreement transactions are finalized. This plan allows for the additional repurchase of up to $200 million of Class A common stock. TKO Group Holdings Inc. (NYSE:TKO) remains focused on disciplined capital deployment and high-quality execution to provide value to its shareholders through these structured financial maneuvers.
TKO Group Holdings Inc. (NYSE:TKO) is a sports company that operates through three segments: UFC, WWE, and IMG. The company also merchandises video games, apparel, equipment, and digital goods.
7. Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the best future stocks to buy for the next 5 years. On March 30, Alnylam Pharmaceuticals presented new clinical and real-world data at the American College of Cardiology’s Annual Scientific Session/ACC.26 regarding its cardiovascular portfolio. The findings highlight the benefits of vutrisiran, which is an RNAi therapeutic that silences transthyretin/TTR at the source, for patients with transthyretin-mediated amyloidosis with cardiomyopathy/ATTR-CM.
Data from the HELIOS-B analysis showed that vutrisiran improved health-related quality of life and functional outcomes, with treatment effects in older patients appearing comparable to those observed in individuals more than a decade younger. The presentation detailed vutrisiran’s efficacy across the disease spectrum, including those with advanced illness and diastolic dysfunction.
Regarding the hypertension pipeline, Alnylam shared pooled Phase 2 safety data for zilebesiran, an investigational RNAi therapeutic designed to provide continuous blood pressure control through biannual dosing. The results support the ongoing evaluation of zilebesiran in the ZENITH Phase 3 Cardiovascular Outcomes Trial, which was initiated in late 2025 to address cardiovascular risk reduction.
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is a biotechnology company that develops therapeutics based on ribonucleic acid interference. The company currently has a range of products in Phase 3, Phase 2, and Phase 1 trials.
6. Takeda Pharmaceutical Company Limited (NYSE:TAK)
Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the best future stocks to buy for the next 5 years. On March 2, Takeda and Protagonist Therapeutics announced that the US FDA accepted the NDA and granted Priority Review for rusfertide. An investigational, first-in-class hepcidin mimetic peptide, rusfertide is intended for the treatment of adults with polycythemia vera/PV. The FDA established a Prescription Drug User Fee Act target action date within Q3 2026. This milestone follows previous Breakthrough Therapy, Orphan Drug, and Fast Track designations granted to the therapeutic.
The regulatory submission is primarily supported by results from the Phase 3 VERIFY study and long-term data from the Phase 2 REVIVE and THRIVE studies. In the VERIFY trial, rusfertide combined with standard of care more than doubled clinical response rates compared to standard care alone. Patients experienced improvements in hematocrit control, a reduction in the need for phlebotomy, and improved patient-reported outcomes regarding fatigue and symptom burden.
Takeda Pharmaceutical Company Limited (NYSE:TAK) and Protagonist entered a worldwide license and collaboration agreement for rusfertide in January 2024. Under this partnership, Protagonist led the development through Phase 3, while Takeda is responsible for the US regulatory strategy and future global filings.
Takeda Pharmaceutical Company Limited (NYSE:TAK) is a healthcare company that develops pharmaceutical products for gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience.
While we acknowledge the potential of TAK to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TAK and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 Best Future Stocks to Buy for the Next 5 Years.
Disclosure: None. None. Follow Insider Monkey on Google News.
